"Mount Sinai Teams With Sanofi, Sema4 On Data-Driven Asthma Study" - Greg Slabodkin
A five-year study of almost 1,200 asthma patients will collect real-world data through molecular profiling of biological samples and digital monitoring of the environment. Mount Sinai Health System is collaborating with biopharmaceutical company Sanofi and predictive health vendor Sema4 – which was spun our last year by Mount Sinai – to provide new insights into the biological mechanisms and other factors implicated in asthma by collecting a wide range of data, including clinical, genomics, immunological, environmental, as well as sensor data from mobile devices. “Asthma is an incredibly complex condition associated with genetics, environmental factors, activity levels, the immune system and more,” said Eric Schadt, PhD, dean for precision medicine at the Icahn School of Medicine at Mount Sinai and chief executive officer of Sema4. “We believe the only way to fully understand asthma is by using sophisticated modeling tools to mine the rich, multi-dimensional data set we aim to generate in this study. This approach could reveal entirely new avenues for alleviating and more effectively treating asthma.”
— Linda Rogers, MD, Associate Professor, Medicine, Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, Clinical Director, Adult Asthma Program, Mount Sinai-National Jewish Health Respiratory Institute
— Eric Schadt, PhD, Dean, Precision Medicine, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, Chief Executive Officer, Sema4
— Andrew Kasarkis, PhD, Vice Chair, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai
— Erik Lium, PhD, Executive Vice President, Mount Sinai Innovation Partners
Additional coverage: The Stamford Advocate
Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind
Dec 04, 2018 View All Press Releases